Navigation Links
Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
Date:5/11/2009

Announces Positive Top Line Results of its Clinical Study of LT-NS001 vs. naproxen and Achievement of Financing Milestone

WALTHAM, Mass., May 11 /PRNewswire/ -- Logical Therapeutics, Inc (Logical), a biotechnology company focused on the development of products that treat diseases associated with inflammation, today announced that Peter A. Lankau has been appointed Chief Executive Officer, and has been elected to the Company's Board of Directors. Mr. Lankau was most recently President and CEO of Endo Pharmaceuticals Inc., a publicly traded specialty pharmaceutical company.

"I am excited to be teaming up with such an experienced group of scientists and investors to develop clinically meaningful and novel products for inflammatory diseases," said Mr. Lankau. "Logical Therapeutics' pipeline includes important medicines for the millions of people who suffer from chronic inflammatory conditions. Logical's lead compound, LT-NS001 will be particularly important for patients whose need for non-steroidal anti-inflammatory treatment is complicated by significant gastrointestinal risks."

Mr. Lankau became President and CEO of Endo Pharmaceuticals in 2005, after having served as President and COO since 2003, and SVP of Commercial Business since 2000. Previously, Mr. Lankau was Vice President, Sales and Marketing at Alpharma, Inc. and held various management positions at Rhone-Poulenc Rorer.

"We are delighted to have Peter join the Logical team and our Board of Directors," said Lutz Giebel, Chairman of Logical Therapeutics, Inc., and the Managing Partner of SV Life Sciences Advisers LLC, a lead investor in Logical, "His experience in leading a growth oriented public company, his execution of numerous business development transactions, and his understanding of the commercially important, and value creating elements of drug development, will help propel Logical toward significant business opportunities
'/>"/>

SOURCE Logical Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
5. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
6. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
7. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
8. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
9. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
10. Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting
11. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015  The strongest ... market is the increasing elderly population, according to ... recent report from the healthcare market research publisher, ... coupled with other risk factors such as obesity ... worldwide. Demand for innovative product designs and the ...
(Date:3/4/2015)... Mass., March 4, 2015 GSI Group Inc. ... "GSI"),  a global leader and supplier of precision photonics ... equipment and advanced industrial technology markets, today reported financial ... Unless otherwise noted, all financial results in this press ... Fourth QuarterDuring the fourth quarter of 2014, GSI ...
(Date:3/4/2015)... March 4, 2015 Amgen (NASDAQ: ... declared a $0.79 per share dividend for the second ... June 5, 2015, to all stockholders of record as ... About Amgen Amgen is committed to ... serious illnesses by discovering, developing, manufacturing and delivering innovative ...
Breaking Medicine Technology:Kalorama: Growing Elderly Population Drives Orthopedic Device Market 2Kalorama: Growing Elderly Population Drives Orthopedic Device Market 3GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 2GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 3GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 4GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 5GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 6GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 7GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 8GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 9GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 10GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 11GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 12GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 13GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 14GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 15GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 16GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 17GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 18GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 19GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 20GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 21GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 22GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 23GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 24GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 25GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 26GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 27GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 28GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 29GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 30GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 31GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 32GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 33Amgen Announces 2015 Second Quarter Dividend 2
(Date:3/4/2015)... March 05, 2015 The Asia-Pacific ... value of $5,632.8 million by 2019, at a ... 2014 to 2019. , Browse through the TOC ... of industry trends and segments, with the help ... , Phthalic Anhydride (PA) is a derivative of ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 When people talk ... the top artists spread across numerous genres, the Houston ... the conversation. Each night during the annual livestock show and ... addition to the other activities being held at the event. ... groups of performers that will try and get the festival ...
(Date:3/4/2015)... March 04, 2015 The federal litigation ... the statin drug caused patients to develop Type 2 ... Court, District of South Carolina. According to court documents, ... March 26, 2015 at 10:00 a.m. In advance of ... a Joint Status report to the Court by March ...
(Date:3/4/2015)... Church, VA (PRWEB) March 04, 2015 ... Four Hours , **FDAnews Webinar**, March 24, 2015 — ... , FDA investigators generally know within four hours of ... If the manufacturer is on their “good” list, they’ll ... doing. If a manufacturer is on the “bad” list, ...
(Date:3/4/2015)... 04, 2015 The ability of ... density assessment and help improve breast cancer risk ... accepted for presentation at the European Congress of ... abstracts - eight posters and 2 session presentations ... breast density and quantitative breast imaging software tools ...
Breaking Medicine News(10 mins):Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 2Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 3Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 2Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 3Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5
... ... await their orders of Xyngular Xyng™ as Zija,s NEW! XM3™ "Happy ... market months before their NEW! Xyng™ product was released and the ... all over the world are calling to become distributors of Zija ...
... The ... H1N1 flu virus as near as your closest electrical outlet. According to the Center for ... in classrooms anywhere can encourage frequent hot-water hand-washing without costly plumbing and in any location ... ...
... (Prozac) and citalopram (Celexa) treatment significantly inhibited disease ... Research led by Sandra Sacre, Ph.D. from the ... UK studied the anti-arthritic potential of these drugs, ... commonly used to treat depression. Both SSRIs ...
... 2010 "The unfortunate truth is that by many measures, ... W. Stubbs, MD, FACP, president of the American College of ... Nation,s Health Care briefing. "We have too many uninsured, ... care is rising faster than we can afford." "Health ...
... ... ... ... ...
... ... ... ... ...
Cached Medicine News:Health News:Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales 2Health News:Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales 3Health News:Angeles Launches New Portable Hot Water Sinks 2Health News:Angeles Launches New Portable Hot Water Sinks 3Health News:Angeles Launches New Portable Hot Water Sinks 4Health News:Prozac and Celexa exhibit anti-inflammatory effects 2Health News:America's health care system in state of decline 2Health News:Alexza to Announce 2009 Year-End Financial Results on Monday, March 8, 2010 2Health News:Alexza to Announce 2009 Year-End Financial Results on Monday, March 8, 2010 3Health News:Alexza to Announce 2009 Year-End Financial Results on Monday, March 8, 2010 4Health News:Alexza to Announce 2009 Year-End Financial Results on Monday, March 8, 2010 5Health News:Alexza to Announce 2009 Year-End Financial Results on Monday, March 8, 2010 6Health News:Wounded Soldier Who Received Historic Cell Transplant Gets Standing Ovation at Diabetes Research Institute Benefit 2Health News:Wounded Soldier Who Received Historic Cell Transplant Gets Standing Ovation at Diabetes Research Institute Benefit 3Health News:Wounded Soldier Who Received Historic Cell Transplant Gets Standing Ovation at Diabetes Research Institute Benefit 4Health News:Wounded Soldier Who Received Historic Cell Transplant Gets Standing Ovation at Diabetes Research Institute Benefit 5Health News:Wounded Soldier Who Received Historic Cell Transplant Gets Standing Ovation at Diabetes Research Institute Benefit 6
Near PT test card/Tumbling E, tumbling hands 5 1/2" X 8"....
9" X 14" translucent plastic may be used with illuminated test cabinet or as a wall chart 20/200 to 20/15....
The PowerLab/4ST is a high-performance recording unit with built-in amplifiers and is suitable for physiology teaching. It has been designed to cover the broad experimental requirements in life scien...
... The PowerLab/4SP is a high-performance data acquisition ... research applications including human and animal physiology, ... engineering. The unit is capable of recording ... (up to 200 000 samples per second ...
Medicine Products: